KAS
AXSM icon

Kemnay Advisory Services’s Axsome Therapeutics AXSM Stock Holding History

Kemnay Advisory Services’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-337
Closed -$57K – 1198
2026
Q1 		$57K Buy
337
+170
+102% +$29.4K 0.01% 226
2025
Q4 		$30.5K Buy
+167
New +$23.3K ﹤0.01% 423

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Kemnay Advisory Services's AXSM Position: Q2 2026 in Review

Kemnay Advisory Services sold out of Axsome Therapeutics (AXSM) in Q2 2026, closing a stake of 337 shares — an estimated $57K sold.

Kemnay Advisory Services first reported a position in AXSM in Q4 2025 and held it in 2 quarters. The position peaked at $57K in Q1 2026. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Kemnay Advisory Services reported no remaining Axsome Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Kemnay Advisory Services sold 337 Axsome Therapeutics shares in Q2 2026, an estimated $57K.
  • Kemnay Advisory Services first reported a position in Axsome Therapeutics in Q4 2025 and held it in 2 quarters.
  • Kemnay Advisory Services's Axsome Therapeutics position peaked at $57K in Q1 2026.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Kemnay Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.